Literature DB >> 1371078

Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia.

D Jonas1, M Lübbert, E S Kawasaki, M Henke, K J Bross, R Mertelsmann, F Herrmann.   

Abstract

The cytogenetic hallmark of chronic myelogenous leukemia (CML) is the Philadelphia chromosome (Ph1), which reflects a chromosomal translocation t(9;22) and a rearrangement of the ABL and bcr genes. This marker is found in all cells arising from the same malignant precursor cell and can be detected in CML cells of the myeloid, monocytic, erythroid, and B-lymphocyte lineage. It is, however, controversial as to whether T lymphocytes of CML patients carry this gene rearrangement. An answer to this question would clarify whether the translocation in CML occurs in a pluripotent hematopoietic stem cell or in a precursor cell already committed to certain lineages, but not the T-cell lineage. To address this question, we established T-cell clones from peripheral venous blood cells of four patients with CML and screened these clones for bcr-abl fusion transcripts by means of polymerase chain reaction and Southern blot analysis. In four T-cell clones of three of these patients, the bcr-abl transcript could be detected. None of 12 T-cell clones of the fourth patient disclosed detectable bcr-abl amplification product. Both CD4+ as well as CD8+ clones displayed fused bcr-abl sequences. These data imply that in CML some but not all T lymphocytes may originate from the Ph1-positive stem cell.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371078

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.

Authors:  T Miyamoto; I L Weissman; K Akashi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  Benign hematopoietic progenitors in chronic myeloid leukemia: current status and future prospects.

Authors:  F Cervantes; C Rozman
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

3.  BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.

Authors:  S S Clark; E Chen; M Fizzotti; O N Witte; V Malkovska
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

Review 4.  Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis.

Authors:  M R Corces-Zimmerman; R Majeti
Journal:  Leukemia       Date:  2014-07-09       Impact factor: 11.528

5.  The majority of T lymphocytes are polyclonal during the chronic phase of chronic myelogenous leukemia.

Authors:  N Tsukamoto; M Karasawa; T Maehara; K Okamoto; H Sakai; T Naruse; K Morita; J Tsuchiya; M Omine
Journal:  Ann Hematol       Date:  1996-02       Impact factor: 3.673

6.  Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood.

Authors:  G Pasternak; L Pasternak
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

Review 7.  Regulation of hematopoietic and leukemic stem cells by the immune system.

Authors:  C Riether; C M Schürch; A F Ochsenbein
Journal:  Cell Death Differ       Date:  2014-07-04       Impact factor: 15.828

Review 8.  Acute Myeloid Leukemia: Aging and Epigenetics.

Authors:  Polina Zjablovskaja; Maria Carolina Florian
Journal:  Cancers (Basel)       Date:  2019-12-31       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.